MedTrace Logo

Micro RNAs to Predict Response to Androgen Deprivation Therapy

NCT02366494 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 42

Last updated 2024-11-25

No results posted yet for this study

Summary

Identify exosomal micro RNA that predict responses to ADT

Conditions

Interventions

DRUG

Bicalutamide

ANDROGEN BLOCKADE

DRUG

Leuprolide

ANDROGEN BLOCKADE

DRUG

Goserelin

ANDROGEN BLOCKADE

DRUG

Triptorelin

ANDROGEN BLOCKADE

DRUG

Docetaxel

Chemo hormonal therapy

DRUG

Abiraterone

Chemo hormonal therapy

DRUG

Apalutamide

Nonsteroidal antiandrogen medication

DRUG

Enzalutamide

Nonsteroidal antiandrogen medication

Sponsors & Collaborators

  • Medical College of Wisconsin

    lead OTHER

Principal Investigators

  • Deepak Kilari, MD · The Medical College of Wisconsin

Eligibility

Min Age
21 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-29
Primary Completion
2021-05-11
Completion
2021-05-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02366494 on ClinicalTrials.gov